NIUM SA

NIUM uses a microfluidics-based human gastrointestinal tract emulator empowered by tailored bioinformatics pipelines to test how nutrition products and drugs affect metabolism with applications in food and healthcare.

We initiated commercialization with multinational food and nutrition companies. R&D Spending is $13.8B in Europe and $21B in the US with 40% of budgets targeting early product development. We secured €120K in revenue in 2022 and on a growth trajectory for 2023. We have secured national and European grants and have IP protection.

NIUM is raising a pre-seed of 750K to continue developing our unique platform, setup our own lab and fuel growth.